^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AB821

    i
    Other names: AB821
    Associations

    News

    Trials
    Company:
    Asher Biotherap
    Drug class:
    CD8 T-cell agonist, IL-21 agonist
    Related drugs:
    Associations

    News

    Trials
    2years
    AB821 is a CD8+ T cell selective IL-21 with enhanced bioavailability that mediates potent anti-tumor activity, cytotoxicity, and expansion of memory CD8+ T cells (SITC 2022)
    AB821 promotes cytotoxicity and memory CD8+ T cells in the context of antigen activation and synergizes with PD1 blockade in PD1-resistant tumors. Clinical development of AB821 is planned.
    PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CD4 (CD4 Molecule) • GZMB (Granzyme B) • IL21 (Interleukin 21)
    |
    AB821